MAP2K4 - Wikipedia
MAP2K4 encodes a dual-specificity kinase that belongs to the Ser/Thr protein kinase family. MAP2K4 phosphorylates MAP kinases in response to various environmental stresses or …
MAP2K4 Gene - GeneCards | MP2K4 Protein | MP2K4 Antibody
Mar 30, 2025 · MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4) is a Protein Coding gene. Diseases associated with MAP2K4 include Colorectal Cancer and Breast Cancer. Among its …
MAP2K4: New kid on the MAP Kinase block - NCI - National Cancer …
As selective MAP2K4 inhibitors have recently been developed, this provides a potentially novel combination treatment strategy for KRAS-mutant cancers 17,18. Therefore, MAP2K4 is a new …
Map2k4 Functions as a Tumor Suppressor in Lung …
MAP2K4 encodes a dual-specificity kinase (mitogen-activated protein kinase kinase 4, or MKK4) that is mutated in a variety of human malignancies, but the biochemical properties of the …
MAP2K4 mitogen-activated protein kinase kinase 4 [ (human)]
MAP2K4 is targeted by genetic inactivation in ovarian cancer and restricted to high grade serous and endometrioid carcinomas in our cohort. These results indicated that MKK4 acts as a tumor …
MAP2K4 - My Cancer Genome
Mitogen-activated protein kinase kinase 4 (MAP2K4) is a gene that encodes a protein that is a member of the MAP kinase family. The protein functions in the signaling of multiple cellular …
MAP2K4 interacts with Vimentin to activate the PI3K/AKT
Nov 25, 2019 · Mitogen-activated protein kinase kinase 4 (MAP2K4) is a member of the mitogen-activated protein kinase (MAPK) activator family. MAPK signaling plays a significant role in cell …
Entry - *601335 - MITOGEN-ACTIVATED PROTEIN KINASE KINASE 4; MAP2K4 …
Jun 6, 2013 · In the SAPK pathway, SAPKs are the dominant JNKs activated in response to a variety of cellular stresses, including treatment with interleukin-beta (147720) and tumor …
MAP2K4 mitogen-activated protein kinase kinase 4 [Homo …
Feb 8, 2025 · Title: Long noncoding RNA HNF1A-AS1 regulates proliferation and apoptosis of glioma through activation of the JNK signaling pathway via miR-363-3p/MAP2K4. microRNA …
MAP3K1 and MAP2K4 mutations are associated with sensitivity …
May 24, 2018 · Our findings suggest that cancers having mutations in MAP3K1 or MAP2K4, which are frequent in tumors of breast, prostate and colon, may respond to MEK inhibitors.